Condition: Advanced Solid Tumor · Metastatic Solid Tumor · Cervical Cancer · Sponsor: GI Innovation, Inc.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or metastatic solid tumors.
This description comes directly from the study's public registry record.
Recruiting sites have contact information. Please contact the sites directly. · +8224042003 · clinical@gi-innovation.com
Always discuss trial participation with your own doctor first.
| Tisch Cancer Institute (TCI), Icahn School of Medicine | New York, New York, United States | Recruiting |
| Carolina Biooncology Institute | Huntersville, North Carolina, United States | Recruiting |
| The Catholic University of Korea Seoul ST.MARY'S Hospital | Seoul, Banpo-daero, South Korea | Recruiting |
| Seoul National University Bundang Hospital | Seoul, Bundang-gu, South Korea | Recruiting |
| Chungnam National University Hospital | Daejeon, Daejeon, South Korea | Recruiting |
| Samsung Medical Center | Seoul, Gangnam, South Korea | Recruiting |
| The Catholic University of Korea St. Vincent's Hospital | Suwon, Kyeonggi-do, South Korea | Recruiting |
| Korea University Anam Hospital | Seoul, Seongbuk-gu, South Korea | Recruiting |
| Ewha Womans University Mokdong Hospital | Seoul, Yangcheon-gu, South Korea | Recruiting |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Recruiting |
| Yonsei University Health System, Severance Hospital | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04977453